

CITATION REPORT

List of articles citing

Labeling Changes and Costs for Clinical Trials
Performed Under the US Food and Drug
Administration Pediatric Exclusivity Extension, 2007
to 2012

DOI: 10.1001/jamainternmed.2018.3933
JAMA Internal Medicine, 2018, 178, 1458-1466.

Source: <https://exaly.com/paper-pdf/70665140/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Costs of pivotal trials and paediatric trials high in USA. <i>PharmacoEconomics & Outcomes News</i> , 2018 , 813, 7-7	0.1	
17	Promoting Pediatric Drug Research and Labeling - Outcomes of Legislation. <i>New England Journal of Medicine</i> , 2019 , 381, 875-881	59.2	11
16	Cancer drug development: The missing links. <i>Experimental Biology and Medicine</i> , 2019 , 244, 663-689	3.7	33
15	Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1671-1675	11.6	7
14	Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 985-994	6.1	3
13	Online Pediatric Research: Addressing Consent, Assent, and Parental Permission. <i>Journal of Law, Medicine and Ethics</i> , 2020 , 48, 129-137	1.2	6
12	Bionetworks, system biology, and superorganisms. 2020 , 57-97		
11	Cost-effectiveness and pricing of caffeine. <i>Seminars in Fetal and Neonatal Medicine</i> , 2020 , 25, 101179	3.7	
10	Estimating The Cost Of Delayed Generic Drug Entry To Medicaid. <i>Health Affairs</i> , 2020 , 39, 1011-1017	7	2
9	Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1018-1025	6.1	4
8	FDA Approval and Regulation of Pharmaceuticals, 1983-2018. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 164-176	27.4	104
7	Reform at the FDA-In Need of Reform. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 123-124	27.4	5
6	Drug Dosing Recommendations for All Patients: A Roadmap for Change. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 65-72	6.1	13
5	Challenges at the interface of science, drug development, and drug approval beyond specific disease areas. 2021 , 271-336		
4	Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021 , 14, 3	3.2	12
3	Conflict of Interest. 2020 , 55-69		
2	The Use of Off-Label Medications in Newborn Infants Despite an Approved Alternative Being Available-Results of a National Survey.. <i>Pharmacy (Basel, Switzerland)</i> , 2022 , 10,	2	

1

How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges. **2022**, 9, 1885

0